What is Radiopharm Theranostics Ltd's earnings per share (EPS)?

Radiopharm Theranostics Ltd (RADX) reported diluted earnings per share of $1000000.00 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Radiopharm Theranostics Ltd Financials

RADX

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE June

This page shows Radiopharm Theranostics Ltd (RADX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RADX FY2025 2026-04-22

External financing, not commercial revenue, is funding the business as losses and cash burn continue despite a sales uptick.

FY2025 revenue reached $3.6M, but operating cash burn also widened to -$36.6M. Against FY2024, that means the business added reported revenue without reducing its dependence on outside funding. The stronger cash balance of $29.1M was therefore financing-led, not earnings-led, supported by $45.4M of financing inflow.

With only $3.6M of revenue against $86.5M of assets, this still behaves more like a capital-consuming platform than a mature sales engine. Even though net loss narrowed to -$38.3M from -$47.9M, the basic operating model did not yet become self-funding.

Liquidity improved materially: cash rose from $18.6M to $29.1M. At the same time, the current ratio moved to 2.7x from 1.3x, showing a wider short-term cushion. Because operating cash flow stayed negative, that cushion came from capital raised rather than from customer receipts.

Financial Health Signals

Financial Profile 39/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Radiopharm Theranostics Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

100

Radiopharm Theranostics Ltd's revenue surged 1114.3% year-over-year to $3.6M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Radiopharm Theranostics Ltd carries a low D/E ratio of 1.02, meaning only $1.02 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Radiopharm Theranostics Ltd's current ratio of 2.67 indicates adequate short-term liquidity, earning a score of 50/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Radiopharm Theranostics Ltd generates a -89.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -175.3% the prior year.

Piotroski F-Score Neutral

4/9

Radiopharm Theranostics Ltd passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.96x

For every $1 of reported earnings, Radiopharm Theranostics Ltd generates $0.96 in operating cash flow (-$36.6M OCF vs -$38.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.6M

YoY+1114.3%

Radiopharm Theranostics Ltd generated $3.6M in revenue in fiscal year 2025. This represents an increase of 1114.3% from the prior year.

EBITDA

N/A

Net Income

-$38.3M

YoY+20.0%

Radiopharm Theranostics Ltd reported -$38.3M in net income in fiscal year 2025. This represents an increase of 20.0% from the prior year.

EPS (Diluted)

$1000000.00

YoY+0.0%

Radiopharm Theranostics Ltd earned $1000000.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$29.1M

YoY+56.8%

Radiopharm Theranostics Ltd held $29.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

2.36B

Radiopharm Theranostics Ltd had 2.36B shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

-1055.3%

YoY+14969.0pp

Radiopharm Theranostics Ltd's net profit margin was -1055.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 14969.0 percentage points from the prior year.

Return on Equity

-89.4%

YoY+85.9pp

Radiopharm Theranostics Ltd's ROE was -89.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 85.9 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

RADX Income Statement

Metric	FY25	FY24	FY23
Revenue	$3.6M+1114.3%	$299K+2.3%	$292K
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A
Income Tax	$103K+7.2%	$96K+153.6%	$38K
Net Income	-$38.3M+20.0%	-$47.9M-38.5%	-$34.6M
EPS (Diluted)	$1000000.000.0%	$1000000.000.0%	$1000000.00

Metric	Q4'25	Q4'24
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	N/A	N/A
SG&A Expenses	N/A	N/A
Operating Income	N/A	N/A
Interest Expense	N/A	N/A
Income Tax	N/A	N/A
Net Income	N/A	N/A
EPS (Diluted)	N/A	N/A

RADX Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$86.5M+20.1%	$72.0M	N/A
Current Assets	$39.9M+74.4%	$22.8M	N/A
Cash & Equivalents	$29.1M+56.8%	$18.6M+58.8%	$11.7M
Inventory	N/A	N/A	N/A
Accounts Receivable	$10.4M+953.3%	$987K-77.9%	$4.5M
Goodwill	N/A	N/A	N/A
Total Liabilities	$43.6M-2.4%	$44.7M	N/A
Current Liabilities	$14.9M-15.0%	$17.6M	N/A
Long-Term Debt	N/A	N/A	N/A
Total Equity	$42.9M+56.7%	$27.4M-40.0%	$45.6M
Retained Earnings	N/A	N/A	N/A

Metric	Q4'25	Q4'24
Total Assets	$86.5M+20.1%	$72.0M
Current Assets	$39.9M+74.4%	$22.8M
Cash & Equivalents	$29.1M+56.8%	$18.6M
Inventory	N/A	N/A
Accounts Receivable	$10.4M+953.3%	$987K
Goodwill	N/A	N/A
Total Liabilities	$43.6M-2.4%	$44.7M
Current Liabilities	$14.9M-15.0%	$17.6M
Long-Term Debt	N/A	N/A
Total Equity	$42.9M+56.7%	$27.4M
Retained Earnings	N/A	N/A

RADX Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$36.6M-59.5%	-$23.0M+1.0%	-$23.2M
Capital Expenditures	N/A	N/A	$45K
Free Cash Flow	N/A	N/A	-$23.2M
Investing Cash Flow	$1.8M+653.3%	-$320K+79.1%	-$1.5M
Financing Cash Flow	$45.4M+50.5%	$30.2M+227.6%	$9.2M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'25	Q4'24
Operating Cash Flow	N/A	N/A
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	N/A	N/A
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

RADX Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	-1055.3%+14969.0pp	-16024.3%-4185.7pp	-11838.6%
Return on Equity	-89.4%+85.9pp	-175.3%-99.4pp	-75.9%
Return on Assets	-44.3%+22.2pp	-66.6%	N/A
Current Ratio	2.67+1.4	1.30	N/A
Debt-to-Equity	1.02-0.6	1.63	N/A
FCF Margin	N/A	N/A	-7951.6%

Metric	Q4'25	Q4'24
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	N/A	N/A
Return on Assets	N/A	N/A
Current Ratio	2.67+1.4	1.30
Debt-to-Equity	1.02-0.6	1.63
FCF Margin	N/A	N/A

Similar Companies

Plus Therapeutics Inc PSTV

$47.4M

Tempest Therapeutics Inc TPST

$26.8M

Renovaro RENB

$32.9M

Barinthus Biotherapeutics plc BRNS

$28.6M

Acrivon Therapeutics, Inc. ACRV

$76.6M

Frequently Asked Questions

What is Radiopharm Theranostics Ltd's annual revenue?

Radiopharm Theranostics Ltd (RADX) reported $3.6M in total revenue for fiscal year 2025. This represents a 1114.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Radiopharm Theranostics Ltd's revenue growing?

Radiopharm Theranostics Ltd (RADX) revenue grew by 1114.3% year-over-year, from $299K to $3.6M in fiscal year 2025.

Is Radiopharm Theranostics Ltd profitable?

No, Radiopharm Theranostics Ltd (RADX) reported a net income of -$38.3M in fiscal year 2025, with a net profit margin of -1055.3%.

What is Radiopharm Theranostics Ltd's net profit margin?

Radiopharm Theranostics Ltd (RADX) had a net profit margin of -1055.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Radiopharm Theranostics Ltd's return on equity (ROE)?

Radiopharm Theranostics Ltd (RADX) has a return on equity of -89.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Radiopharm Theranostics Ltd's operating cash flow?

Radiopharm Theranostics Ltd (RADX) generated -$36.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Radiopharm Theranostics Ltd's total assets?

Radiopharm Theranostics Ltd (RADX) had $86.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Radiopharm Theranostics Ltd have outstanding?

Radiopharm Theranostics Ltd (RADX) had 2.36B shares outstanding as of fiscal year 2025.

What is Radiopharm Theranostics Ltd's current ratio?

Radiopharm Theranostics Ltd (RADX) had a current ratio of 2.67 as of fiscal year 2025, which is generally considered healthy.

What is Radiopharm Theranostics Ltd's debt-to-equity ratio?

Radiopharm Theranostics Ltd (RADX) had a debt-to-equity ratio of 1.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Radiopharm Theranostics Ltd's return on assets (ROA)?

Radiopharm Theranostics Ltd (RADX) had a return on assets of -44.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Radiopharm Theranostics Ltd's cash runway?

Based on fiscal year 2025 data, Radiopharm Theranostics Ltd (RADX) had $29.1M in cash against an annual operating cash burn of $36.6M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Radiopharm Theranostics Ltd's Piotroski F-Score?

Radiopharm Theranostics Ltd (RADX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Radiopharm Theranostics Ltd's earnings high quality?

Radiopharm Theranostics Ltd (RADX) has an earnings quality ratio of 0.96x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Radiopharm Theranostics Ltd?

Radiopharm Theranostics Ltd (RADX) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.